Bladder Cancer

>

Latest News

Results from the phase 3 CHECKMATE-901 trial led to the approval of nivolumab plus cisplatin and gemcitabine for patients with unresectable or metastatic urothelial carcinoma.
FDA Approves First-line Nivolumab Combo for Urothelial Carcinoma

March 7th 2024

Results from the phase 3 CHECKMATE-901 trial led to the approval of nivolumab plus cisplatin and gemcitabine for patients with unresectable or metastatic urothelial carcinoma.

Enfortumab Vedotin Combo Earns Priority Review in Japan for Bladder Cancer | Image Credit: © SciePro - stock.adobe.com.
Enfortumab Vedotin Combo Earns Priority Review in Japan for Bladder Cancer

February 19th 2024

Investigators report clinical benefit with sacituzumab govitecan plus pembrolizumab across all prespecified patient subgroups with metastatic urothelial cancer in cohort 3 of the phase 2 TROPHY-U-01 trial.
Sacituzumab Govitecan Combo Shows Encouraging Responses in Bladder Cancer

February 15th 2024

Interim findings from a phase 3 trial support adjuvant pembrolizumab as a new therapeutic option for those with muscle-invasive urothelial carcinoma at high risk of recurrence.
Pembrolizumab Improves DFS Vs Observation in Muscle-Invasive Urothelial Carcinoma

February 8th 2024

Combining pembrolizumab with cabozantinib produces encouraging efficacy in platinum-ineligible patients with advanced urothelial carcinoma, says Rohit K. Jain, MD, MPH.
Pembrolizumab Combo Yields Efficacy in Advanced Urothelial Carcinoma

February 3rd 2024

Video Series
Video Interviews
Podcasts
Jun Gong, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on elderly patients with muscle-invasive bladder cancer.

More News